Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb open-label non-controlled study of switching from intravenous to subcutaneous rituximab in first-line CD20+ follicular and diffuse large B-cell non-Hodgkin lymphoma
2013-001118-14Phase 3Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Roche Farma, S.A. Primary endpoints: Incidence of administration-related reactions and Overall safety profile of subcutaneous rituximab. Started Aug 2013; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2013-001118-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001118-14.